查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1601120

新型药物输送系统市场：按给药途径、模式和最终用户划分 - 2025-2030 年全球预测

Novel Drug Delivery Systems Market by Route of Administration, Mode, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年新型给药系统市值为138.3亿美元，预计2024年将达150亿美元，复合年增长率为9.17%，2030年将达255.7亿美元。

调查方法涵盖先进技术，旨在以受控方式输送药物化合物并改善治疗结果。 NDDS 至关重要，因为它可以提高药物的生物有效性、标靶特异性、减少给药频率并最大限度地减少副作用。这些系统在肿瘤学、神经病学、慢性病和其他精确药物传输至关重要的领域中得到了高度利用。最终用途范围主要包括医院、诊所和研究机构，它们是创新药物传输技术的狂热消费者。

主要市场统计
基准年[2023] 138.3亿美元
预测年份 [2024] 150亿美元
预测年份 [2030] 255.7亿美元
复合年增长率（%） 9.17%

主要市场驱动因素包括慢性病的增加、生物技术的技术进步以及製药公司研发投资的增加。老年人口的增加和对有效疾病管理的需求也将推动市场成长。目前的商机在于奈米技术应用、个人化医疗、生物分解性的输送系统以及非侵入性输送方法（例如经皮吸收贴片和吸入器）的开发。为了利用这些机会，公司应专注于协作研究、策略伙伴关係以及智慧给药系统的人工智慧和物联网的整合。

然而，高开发成本、严格的法律规范以及复杂的生物相互作用所导致的潜在安全问题等挑战仍然存在，这可能会阻碍市场成长。此外，製药公司经常面临智慧财产权问题，这些问题可能会阻碍创新和市场进入。专注于合规业务，同时精简研发成本至关重要。此外，改善以患者为中心的输送系统、扩展到新兴市场以及解决需求未满足的治疗领域是创新的最佳途径。市场的竞争性和动态性要求持续创新和策略敏捷性。透过优先考虑以客户为中心的创新并利用尖端材料科学，公司可以实现最佳成长并保持市场相关性。

市场动态：揭示快速发展的新型给药系统市场的关键市场洞察

新药物输送系统的市场正因供需的动态交互作用而转变。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 慢性病盛行率和老年人口显着增加
    • 控制释放技术的进展
    • 政府核准新的药物输送系统
  • 市场限制因素
    • 与新型药物输送系统相关的现有局限性
  • 市场机会
    • 不断进步开发新的药物输送系统
    • 越来越多采用自行注射装置
  • 市场挑战
    • 提供治疗和药物所需的併发症和专业知识

波特五力：开拓新型给药系统市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势、解决弱点并避免潜在的挑战，以确保更强大的市场地位。

PESTLE分析：了解外部对新给药系统市场的影响

外部宏观环境因素在塑造新型药物传输系统市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解新型给药系统市场的竞争状况

对新型药物输送系统市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 新型给药系统市场供应商定位矩阵绩效评估

FPNV 定位矩阵是评估新型药物传输系统市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。四个象限清楚且准确地划分供应商，帮助使用者辨识最能满足其策略目标的合作伙伴和解决方案。

本报告提供了涵盖关键重点领域的全面市场分析：

1. 市场渗透率：对当前市场环境的详细回顾，包括行业主要企业的大量资料。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 慢性病盛行率和老年人口显着增加
      • 控制释放技术的进展
      • 政府核准新的给药系统
    • 抑制因素
      • 与新药物输送系统相关的现有限制
    • 机会
      • 新型药物输送系统的开发不断取得进展
      • 越来越多采用自行注射装置
    • 任务
      • 施用治疗剂和药物所需的併发症和专业知识
  • 市场区隔分析
    • 给药途径：在慢性病管理中越来越多地采用注射给药系统
    • 最终用户：预算限制和容纳更多病患的需求正在增加医院中新型给药系统的使用。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境
  • 客户客製化

第六章 新药物输送系统市场：依给药途径

  • 注射给药系统
  • 口服给药系统
  • 肺部给药系统
  • 经皮给药系统

第七章按模式分類的新给药系统市场

  • 受管制药物传输系统
  • 调控药物传输系统
  • 标靶给药系统

第八章新药物输送系统市场：依最终用户分类

  • 医院
  • 研究中心
  • 专科诊所

第九章北美及南美新给药系统市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区新型给药系统市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲新型给药系统市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • 全新的一站式药物输送商店
    • Viridian Therapeutics 宣布与药物传输创新者 Enable Injections 合作
    • Kindeva Drug Delivery 收购高峰会 Biosciences

公司名单

  • Novartis AG
  • Societal CDMO
  • Johnson & Johnson Services, Inc.
  • AstraZeneca Plc
  • Abbott Laboratories
  • Sanofi SA
  • Terumo Medical Corporation
  • Pfizer Inc.
  • Thermo Fisher Scientific Inc.
  • Enable Injections, Inc.
  • Pacira BioSciences, Inc.
  • Bristol Myers Squibb Company
  • Lonza Group Ltd.
  • Spectrum Pharmaceuticals, Inc.
  • Cospheric LLC
  • Polysciences Inc.
  • Insulet Corporation
  • Bayer AG
  • West Pharmaceutical Services, Inc.
  • Mo-Sci Corporation
  • Merck KGaA
  • Boston Scientific Corporation
  • Merit Medical Systems, Inc.
  • GlaxoSmithKline PLC
  • F. Hoffmann-La Roche Ltd.
Product Code: MRR-02026C4CB9B9

The Novel Drug Delivery Systems Market was valued at USD 13.83 billion in 2023, expected to reach USD 15.00 billion in 2024, and is projected to grow at a CAGR of 9.17%, to USD 25.57 billion by 2030.

The scope of Novel Drug Delivery Systems (NDDS) encompasses advanced methodologies designed to deliver pharmaceutical compounds in a controlled manner to achieve improved therapeutic outcomes. NDDS are essential because they enhance drug bioavailability, target specificity, reduce dosing frequency, and minimize side effects. These systems are highly applicable in areas such as oncology, neurology, and chronic conditions where precise drug delivery is paramount. The end-use scope primarily includes hospitals, clinics, and research institutes, which are avid consumers of innovative drug delivery technologies.

KEY MARKET STATISTICS
Base Year [2023] USD 13.83 billion
Estimated Year [2024] USD 15.00 billion
Forecast Year [2030] USD 25.57 billion
CAGR (%) 9.17%

Key market drivers include the rising prevalence of chronic diseases, technological advancements in biotechnology, and increased R&D investments by pharmaceutical companies. The growing geriatric population and the need for efficient disease management also bolster market growth. Current opportunities lie in nanotechnology applications, personalized medicine, biodegradable delivery systems, and the development of non-invasive delivery methods like transdermal patches and inhalers. To capitalize on these opportunities, businesses should focus on collaborative research, strategic partnerships, and the integration of AI and IoT for smart drug delivery systems.

Nevertheless, challenges such as high development costs, stringent regulatory frameworks, and potential safety issues due to complex biological interactions persist, potentially impeding market growth. Moreover, pharmaceutical companies often face intellectual property rights issues, which can stall innovation and market entry. Rationalizing R&D expenditure while focusing on regulatory-compliant practices is crucial. Additionally, refining patient-centric delivery systems, expanding to emerging markets, and addressing therapeutic areas with unmet needs represent the best innovation avenues. The market's nature is highly competitive and dynamic, requiring continuous innovation and strategic agility. By prioritizing customer-centric innovation and leveraging cutting-edge materials science, companies can achieve optimal growth and maintain market relevance.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Novel Drug Delivery Systems Market

The Novel Drug Delivery Systems Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Prevalence of Chronic Diseases and Significant Rise in Geriatric Population
    • Advancements in Controlled Drug Release Technologies
    • Government Approvals for Novel Drug Delivery Systems
  • Market Restraints
    • Existing Limitations Associated with Novel Drug Delivery System
  • Market Opportunities
    • Ongoing Advancements for Development of Novel Drug Delivery Systems
    • Rising Adoption of Self-Injectable Devices
  • Market Challenges
    • Complications and Expertise Required in Delivering Therapeutics and Drugs

Porter's Five Forces: A Strategic Tool for Navigating the Novel Drug Delivery Systems Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Novel Drug Delivery Systems Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Novel Drug Delivery Systems Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Novel Drug Delivery Systems Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Novel Drug Delivery Systems Market

A detailed market share analysis in the Novel Drug Delivery Systems Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Novel Drug Delivery Systems Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Novel Drug Delivery Systems Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Novel Drug Delivery Systems Market, highlighting leading vendors and their innovative profiles. These include Novartis AG, Societal CDMO, Johnson & Johnson Services, Inc., AstraZeneca Plc, Abbott Laboratories, Sanofi S.A., Terumo Medical Corporation, Pfizer Inc., Thermo Fisher Scientific Inc., Enable Injections, Inc., Pacira BioSciences, Inc., Bristol Myers Squibb Company, Lonza Group Ltd., Spectrum Pharmaceuticals, Inc., Cospheric LLC, Polysciences Inc., Insulet Corporation, Bayer AG, West Pharmaceutical Services, Inc., Mo-Sci Corporation, Merck KGaA, Boston Scientific Corporation, Merit Medical Systems, Inc., GlaxoSmithKline PLC, and F. Hoffmann-La Roche Ltd..

Market Segmentation & Coverage

This research report categorizes the Novel Drug Delivery Systems Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Route of Administration, market is studied across Injectable Drug Delivery Systems, Oral Drug Delivery Systems, Pulmonary Drug Delivery Systems, and Transdermal Drug Delivery Systems.
  • Based on Mode, market is studied across Controlled Drug Delivery Systems, Modulated Drug Delivery Systems, and Targeted Drug Delivery Systems.
  • Based on End-User, market is studied across Hospital, Research Centers, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of Chronic Diseases and Significant Rise in Geriatric Population
      • 5.1.1.2. Advancements in Controlled Drug Release Technologies
      • 5.1.1.3. Government Approvals for Novel Drug Delivery Systems
    • 5.1.2. Restraints
      • 5.1.2.1. Existing Limitations Associated with Novel Drug Delivery System
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing Advancements for Development of Novel Drug Delivery Systems
      • 5.1.3.2. Rising Adoption of Self-Injectable Devices
    • 5.1.4. Challenges
      • 5.1.4.1. Complications and Expertise Required in Delivering Therapeutics and Drugs
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Route of Administration: Rising adoption of injectable drug delivery systems for chronic disease management
    • 5.2.2. End-User: Increasing use of novel drug delivery systems in the hospital due to budget constraints and the necessity to cater to a larger patient base
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental
  • 5.5. Client Customization

6. Novel Drug Delivery Systems Market, by Route of Administration

  • 6.1. Introduction
  • 6.2. Injectable Drug Delivery Systems
  • 6.3. Oral Drug Delivery Systems
  • 6.4. Pulmonary Drug Delivery Systems
  • 6.5. Transdermal Drug Delivery Systems

7. Novel Drug Delivery Systems Market, by Mode

  • 7.1. Introduction
  • 7.2. Controlled Drug Delivery Systems
  • 7.3. Modulated Drug Delivery Systems
  • 7.4. Targeted Drug Delivery Systems

8. Novel Drug Delivery Systems Market, by End-User

  • 8.1. Introduction
  • 8.2. Hospital
  • 8.3. Research Centers
  • 8.4. Specialty Clinics

9. Americas Novel Drug Delivery Systems Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Novel Drug Delivery Systems Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Novel Drug Delivery Systems Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Novel drug delivery one-stop shop
    • 12.3.2. Viridian Therapeutics Announces Partnership with Drug Delivery Innovator Enable Injections
    • 12.3.3. Kindeva Drug Delivery acquires Summit Biosciences

Companies Mentioned

  • 1. Novartis AG
  • 2. Societal CDMO
  • 3. Johnson & Johnson Services, Inc.
  • 4. AstraZeneca Plc
  • 5. Abbott Laboratories
  • 6. Sanofi S.A.
  • 7. Terumo Medical Corporation
  • 8. Pfizer Inc.
  • 9. Thermo Fisher Scientific Inc.
  • 10. Enable Injections, Inc.
  • 11. Pacira BioSciences, Inc.
  • 12. Bristol Myers Squibb Company
  • 13. Lonza Group Ltd.
  • 14. Spectrum Pharmaceuticals, Inc.
  • 15. Cospheric LLC
  • 16. Polysciences Inc.
  • 17. Insulet Corporation
  • 18. Bayer AG
  • 19. West Pharmaceutical Services, Inc.
  • 20. Mo-Sci Corporation
  • 21. Merck KGaA
  • 22. Boston Scientific Corporation
  • 23. Merit Medical Systems, Inc.
  • 24. GlaxoSmithKline PLC
  • 25. F. Hoffmann-La Roche Ltd.

LIST OF FIGURES

  • FIGURE 1. NOVEL DRUG DELIVERY SYSTEMS MARKET RESEARCH PROCESS
  • FIGURE 2. NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. NOVEL DRUG DELIVERY SYSTEMS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. NOVEL DRUG DELIVERY SYSTEMS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. NOVEL DRUG DELIVERY SYSTEMS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. NOVEL DRUG DELIVERY SYSTEMS MARKET DYNAMICS
  • TABLE 7. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INJECTABLE DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ORAL DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PULMONARY DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TRANSDERMAL DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CONTROLLED DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODULATED DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TARGETED DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. NOVEL DRUG DELIVERY SYSTEMS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 148. NOVEL DRUG DELIVERY SYSTEMS MARKET, FPNV POSITIONING MATRIX, 2023